New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 16, 2014
04:55 EDTVCYT, VCYT, VCYT, VCYT, VCYT, VCYT, AZN, AZN, AZN, AZN, AZN, AZN, INSM, INSM, INSM, INSM, INSM, INSM, ITMN, ITMN, ITMN, ITMN, ITMN, ITMN, XNCR, XNCR, XNCR, XNCR, XNCR, XNCRAmerican Thoracic Society to hold a conference
ATS 2014 San Diego to be held on May 16-21.
News For VCYT;AZN;INSM;ITMN;XNCR From The Last 14 Days
Check below for free stories on VCYT;AZN;INSM;ITMN;XNCR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 25, 2014
11:11 EDTITMNOptions with decreasing implied volatility
Options with decreasing implied volatility: AMPE FOLD ITMN AEO DKS WUBA URBN SPLS YOKU GME
10:54 EDTITMNHigh option volume stocks
Subscribe for More Information
10:40 EDTITMNBiotechs rise after InterMune acquired by Roche
Subscribe for More Information
10:00 EDTITMNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:11 EDTITMNOn The Fly: Pre-market Movers
Subscribe for More Information
08:24 EDTITMNRoche to hold a conference call
CEO Schwan and CFO Hippe discuss the acquisition of InterMune on a conference call to be held on August 25 at 9 am. Webcast Link
07:11 EDTITMNInterMune volatility expected to move on Roche acquiring for $8.3B
Subscribe for More Information
06:39 EDTITMNInterMune downgraded to Hold from Buy at Stifel
Roche (RHHBY) is buying InterMune (ITMN) in a deal valued at $8.3B, or $74 per a share.
06:29 EDTAZNPfizer mulls possible AstraZeneca offer options, FT says
Subscribe for More Information
August 24, 2014
20:27 EDTITMNRoche drops pursuit for remainder of Japan's Chugai, Bloomberg says
Subscribe for More Information
13:41 EDTITMNRoche to acquire InterMune for $74.00 per share
Roche (RHHBY) and InterMune (ITMN) announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of $74.00 per share in an all-cash transaction. This corresponds to a total transaction value of $8.3B on a fully diluted basis. This offer represents a premium of 38% to InterMune's closing price on August 22 and a premium of 63% to InterMune's unaffected closing price on August 12. The merger agreement has been approved by the boards of InterMune and Roche. Under the terms of the merger agreement, Roche will commence a tender offer no later than August 29 to acquire all outstanding shares of InterMune common stock, and InterMune will file a recommendation statement containing the unanimous recommendation of the InterMune board that InterMune's shareholders tender their shares to Roche. The transaction is expected to be neutral to core earnings per share in 2015 and accretive from 2016 onwards. The acquisition of InterMune, a Brisbane, California based biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases, will allow Roche to broaden and strengthen its respiratory portfolio globally. Roche plans a smooth transition of InterMune employees and operations into the Roche organization, ensuring readiness for an expected launch of pirfenidone in the US in 2014. The closing of the transaction is expected to take place in 2014.
August 22, 2014
10:07 EDTAZNOptions with increasing implied volatility: ORPH EXAS AZN
Subscribe for More Information
05:19 EDTAZNStocks with implied volatility movement; JRJC AZN
Subscribe for More Information
August 21, 2014
10:14 EDTITMNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:54 EDTAZNPotential Pfizer, AstraZeneca deal seen around year-end, Reuters says
Investors and analysts see Pfizer (PFE) making another attempt to acquire AstraZeneca (AZN) around year-end, even though talks between the two can resume on August 26 per British takeover rules, Reuters reports. Reference Link
07:47 EDTAZNPfizer looking at new targets, including Actavis, Bloomberg reports
While it weighs another attempt to acquire AstraZeneca (AZN), Pfizer is considering other overseas alternatives, including Actavis (ACT), Bloomberg reports, citing people familiar with the matter. Pfizer prefers to reach a deal with AstraZeneca, and a move on another company is unlikely "anytime soon," Bloomberg adds, citing its sources. Shares of Actavis are rising 3%, or $6.65, to $230.01 in pre-market trading, while AstraZeneca is up 2% to $72.59. Reference Link
05:42 EDTAZNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
05:22 EDTITMNInterMune downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded InterMune to Market Perform citing valuation.
August 20, 2014
05:53 EDTITMNStocks with implied volatility movement; NGD ITMN
Subscribe for More Information
August 19, 2014
07:01 EDTAZNDOJ closes investigation into PLATO Brilinta clinical trial, plans no action
AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with BRILINTA tablets. The government is not planning any further action. Pascal Soriot, CEO, said: “We welcome the Department of Justice’s decision not to pursue further action. We have always had absolute confidence in the integrity of the PLATO trial and we are proud of the important benefit BRILINTA offers to patients around the world suffering from acute coronary syndrome. As one of AstraZeneca’s growth platforms, we remain committed to delivering the full potential of this important medicine.” As part of our continued commitment to advancing the science behind cardiovascular medicine, AstraZeneca has initiated a clinical trial program for BRILINTA, its largest program involving more than 80,000 patients worldwide.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use